![Special Analysis: Two Key Legislative Initiatives Labs Should Know About](https://www.g2intelligence.com/wp-content/uploads/2024/03/Apr24.LIA_.SpecialAnalysis.PriceTransparency-iStock-1317706831-1100x800-1-1080x675.jpg)
Special Analysis: Two Key Legislative Initiatives Labs Should Know About
Though potential FDA LDTs regulation has drawn a lot of attention, other efforts could also have long-term effects on how labs do business.
Though potential FDA LDTs regulation has drawn a lot of attention, other efforts could also have long-term effects on how labs do business.
Though IVD and commercial lab Q3 2023 earnings reports held promising signs, Q4 2024 and FY2023 results tell a different story.
Partnership between Mindera and PBM aims to optimize treatment matches for the disorder, as some drugs cost nearly six figures annually
The ALZpath DX assay is less invasive than other diagnostic tests, and may give patients diagnosed with Alzheimer’s more time to plan
The FDA is adding International Organization for Standardization (ISO) guidelines to its “good manufacturing” requirements
The impending legislation that may determine Medicare lab fees from 2025 onward
This webinar highlights internal processes regarding diagnostics for Group A Streptococcus, and explains how these results benefit patients, providers, and staff
This webinar offers expert insight and advice on how adaptability helps lab staffers find suitable candidates for their organizations
This webinar examines the adoption of automation technologies within clinical laboratories, and offers resources to leverage lab automation’s transformative potential in healthcare settings
This webinar will reveal how audits turn actionable data into operational efficiencies and opportunities for improvement, which improves the financial health and sustainability of your laboratory